Biomarker Dynamics and Long-Term Treatment Outcomes in Breast Cancer Patients with Residual Cancer Burden after Neoadjuvant Therapy

A residual cancer burden after neoadjuvant therapy (NAT) for breast cancer (BC) is associated with worse treatment outcomes compared to patients who achieved pathologic complete remission. This single-institutional retrospective study of 767 consecutive patients, including 468 patients with assessab...

Descripción completa

Detalles Bibliográficos
Autores principales: Holanek, Milos, Selingerova, Iveta, Fabian, Pavel, Coufal, Oldrich, Zapletal, Ondrej, Petrakova, Katarina, Kazda, Tomas, Hrstka, Roman, Poprach, Alexandr, Zvarikova, Maria, Bilek, Ondrej, Svoboda, Marek
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9318288/
https://www.ncbi.nlm.nih.gov/pubmed/35885644
http://dx.doi.org/10.3390/diagnostics12071740

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9318288/
https://www.ncbi.nlm.nih.gov/pubmed/35885644
http://dx.doi.org/10.3390/diagnostics12071740

Ejemplares similares